What is Vivet Therapeutics?
Vivet Therapeutics is a specialized biotechnology firm dedicated to the creation of advanced gene therapies for rare genetic disorders. The company's core pipeline focuses on liver-directed AAV products, specifically targeting conditions such as Cerebrotendinous Xanthomatosis, Progressive Familial Intrahepatic Cholestasis, and Wilson's disease. By addressing the critical challenge of neutralizing antibodies, Vivet Therapeutics aims to significantly expand patient access to life-changing medical interventions. Their market position is defined by a rigorous scientific approach to orphan diseases, where they serve as a vital bridge between cutting-edge research and clinical application for patients who currently lack effective treatment options.
How much funding has Vivet Therapeutics raised?
Vivet Therapeutics has raised a total of $46.2M across 2 funding rounds:
Series A
$40.9M
Other Financing Round
$5.3M
Series A (2017): $40.9M with participation from Ysios Capital, Kurma Partners, Columbus Venture Partners SGEIC, HealthCap Partners, and Novartis Venture Fund
Other Financing Round (2024): $5.3M led by Government of France
Key Investors in Vivet Therapeutics
Ysios Capital
A leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, focusing on novel therapies for high unmet medical needs.
Kurma Partners
A prominent European healthcare and biotechnology investor that transforms disruptive scientific discoveries into advanced medical solutions through various maturity stages.
Novartis Venture Fund
The venture arm of a global pharmaceutical manufacturer specializing in the research and development of innovative medications across multiple therapeutic areas.
What's next for Vivet Therapeutics?
With the successful completion of this major strategic investment, Vivet Therapeutics is poised to enter a critical phase of operational scaling and clinical advancement. The company will likely prioritize the expansion of its AAV-based therapeutic pipeline, focusing on accelerating ongoing trials and optimizing manufacturing processes to overcome existing barriers in gene therapy delivery. Strategic resource allocation will be directed toward strengthening their intellectual property portfolio and fostering partnerships that enhance their ability to navigate the global regulatory environment. As the company matures, the focus will shift toward achieving key clinical milestones that validate their platform's efficacy, ultimately aiming to deliver long-term value to both patients and stakeholders in the global healthcare ecosystem.
See full Vivet Therapeutics company page
